Could immunotherapy let some stomach cancer patients skip surgery?
Disease control
Not yet recruiting
This study looks at whether a combination of two immunotherapy drugs (Durvalumab and Tremelimumab) can control advanced stomach cancers with specific genetic features (dMMR/MSI-H) well enough to avoid surgery. The trial enrolls 12 adults who would normally need chemotherapy and s…
Sponsor: Yong Zhou • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC